Pfizer Inc. (PFE)

36.92
0.01 0.03
NYSE : Health Technology
Prev Close 36.93
Open 36.83
Day Low/High 36.70 / 37.09
52 Wk Low/High 33.97 / 46.47
Volume 12.65M
Avg Volume 20.53M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 204.93B
EPS 1.90
P/E Ratio 12.78
Div & Yield 1.44 (3.85%)
Jim Cramer: When Is a Miss Not a Miss?

Jim Cramer: When Is a Miss Not a Miss?

When the stock's inexpensive, hated and devoid of love -- that's when.

Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends

Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends

Pfizer posted solid fourth quarter earnings Tuesday but issued weaker-than-expected 2019 guidance as the exclusivity of its key epilepsy treatment Lyrica comes to and end.

Dow Closes Modestly Higher Ahead of Apple Earnings

Dow Closes Modestly Higher Ahead of Apple Earnings

The Dow Jones Industrial Average posted modest gains Tuesday ahead of financial results from tech bellwether Apple Inc.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Apple, AMD, PG&E, Huawei and the Federal Reserve - 5 Things You Must Know

Apple, AMD, PG&E, Huawei and the Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed amid worries that a U.S. decision to pursue criminal charges against the chief financial officer of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies; the Fed begins a two-day meeting Tuesday; Apple, AMD, Verizon, Pfizer and 3M report earnings Tuesday; PG&E, the nation's largest utility, files for Chapter 11 bankruptcy protection.

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2018 and provided 2019 financial guidance.

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer And Lilly Announce Top-Line Results From Second Phase 3 Study Of Tanezumab In Osteoarthritis Pain

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.

Stocks Mixed as US-China Tensions Escalate; Dollar Dips Ahead of Fed Meeting

Stocks Mixed as US-China Tensions Escalate; Dollar Dips Ahead of Fed Meeting

Global stocks were mixed Tuesday, with Wall Street futures drifting into the red, as investors worried that a U.S. decision to pursue criminal charges against the CFO of China's biggest tech company could stall progress in trade negotiations between the world's two biggest economies that are set to resume this week.

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

Caterpillar Profit Warning Pounds Dow Futures as US Earnings Take Center Stage

Caterpillar Profit Warning Pounds Dow Futures as US Earnings Take Center Stage

U.S. equity futures fell sharply lower Monday as a profit warning from industrial equipment maker Caterpillar cast a pall over the busiest week of the fourth quarter earnings season as markets shifted focus to a series of major event risks and blue chip reports in the week ahead.

Stocks Drift Lower as Shutdown Rally Fades, Focus Shifts to Earnings and Fed

Stocks Drift Lower as Shutdown Rally Fades, Focus Shifts to Earnings and Fed

Global stocks drifted lower Monday as last week's late-hour rally on Wall Street, sparked by a surprise concession from President Donald Trump to end the 35-day government shutdown, fizzled in overnight trading as markets shifted focus to a series of major event risks and blue chip corporate earnings in the day ahead.

U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.

Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion

Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion

Johnson & Johnson posted stronger-than-expected fourth quarter earnings Tuesday and forecast a modest increase in full year sales for 2019 that would take its top line past $81 billion.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

US FDA Accepts Regulatory Submissions For Review Of Tafamidis To Treat Transthyretin Amyloid Cardiomyopathy

US FDA Accepts Regulatory Submissions For Review Of Tafamidis To Treat Transthyretin Amyloid Cardiomyopathy

Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

What Is Nasdaq and How Is It Different From the Dow?

What Is Nasdaq and How Is It Different From the Dow?

Nasdaq is an American stock market and the home of stocks that make up major indexes like the Nasdaq Composite and Nasdaq 100.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Pfizer Initiates Phase 2b/3 Clinical Trial For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Moderate To Severe Alopecia Areata

Pfizer Initiates Phase 2b/3 Clinical Trial For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Moderate To Severe Alopecia Areata

Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss...

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37 th Annual J.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap

Jim Cramer explains the art and science of technical analysis.

TheStreet Quant Rating: B (Buy)